🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

This week at #SABCS24, we will share our latest clinical and real-world data in patients with #EBC at high risk of recurrence, regardless of nodal involvement. We’re proud to help evolve care, so many more people can lower their risk of cancer recurrence. #bcsm

Fear. Courage. Hope. These are just a few feelings expressed by people with #breastcancer at the Novartis exhibit at #SABCS24. These raw and honest perspectives can help others feel less alone in their personal journey, and inspire all of us to continue reimagining medicine,

Innovation is at the heart of what we do. This #ASH24 and #SABCS24, we showcased our commitment to pushing the boundaries of science to help shape a future where patients living with cancer have greater hope. #NovartisUS #ReimaginingMedicine

We reflected on the importance of patient voices during a summit with medical experts and advocates at #ASCO2024. Open dialogue with care teams is crucial to improving care for those living with chronic myeloid leukemia. Together, we can make a difference. 🔗Learn more:

Today, we are proud to announce our role as Lead Founding Partner of ZERO Prostate Cancer's Blitz The Barriers. Together, we’ll improve outcomes among populations who are greatly impacted by #prostatecancer. #ReimaginingMedicine

Partnering with ZERO Prostate Cancer is a demonstration of our deep commitment to closing gaps faced by people with #prostatecancer and supporting better health care. #ReimaginingMedicine

Novartis highlights commitment to hidradenitis suppurativa and chronic spontaneous urticaria at AAAAI and AAD annual congresses. bit.ly/4ilKwCb

Partnering with Susan G. Komen and other leading advocacy voices to launch the Alliance for Breast Cancer Policy is a testament to our collective commitment to improving outcomes for people affected by #breastcancer. Alliance for Breast Cancer Policy

We are joining the roster as the NFL’s first-ever corporate pharmaceutical partner! This collaboration is designed to bring critical health conversations to the forefront, making preventive care and early detection more accessible for fans everywhere. 🤝

Today’s regulatory milestone represents a step forward for patients, loved ones and providers who have been in need of more options to treat advanced prostate cancer earlier. go.novartis.social/4jdekBs #NovartisUS #ReimaginingMedicine

#News: We are expanding our US-based manufacturing and R&D footprint with a planned $23B investment over the next 5 years. 🔗 go.novartis.social/3RHiyVV #NovartisUS

As a member of Alliance for Breast Cancer Policy, we’re raising awareness about the need to remove barriers to #breastcancer care through policies like the Access for Breast Cancer Diagnosis (ABCD) Act. Now we need to get Congress’s attention: yourattentionplease.com #ReimaginingMedicine

#News: We’re excited to announce our upcoming oncology and hematology data that has been recently accepted at ASCO Annual Meeting and European Hematology Association 2025 Congress. bit.ly/43sqJfz #ASCO25 #EHA2025

As a local sponsor of The Leukemia & Lymphoma Society #BloodCancer Conferences, we're grateful to partner with a group whose commitment to the blood cancer community mirrors our own, especially in empowering people living with chronic myeloid leukemia to speak up about their treatment journeys.

From reimagining the impossible to forging partnerships that make us unstoppable as a community, see how we are #ReimaginingMedicine, together.​ Learn more: go.novartis.social/3FfZmMH #NovartisUS

#NEWS: We are sharing a new sub-analysis of data on patients with HR+/HER2- early #breastcancer across various ages, including younger patients. Learn more: go.novartis.social/4jz6X74 #NovartisUS #ASCO25 #BCSM

#News: Phase III PSMAddition trial demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer. go.novartis.social/4jzLY42

The NYSE welcomes ZERO Prostate Cancer & Novartis to celebrate Blitz the Barriers—which aims to be the most ambitious prostate cancer initiative in U.S. history, with a goal of saving 100,000 lives by 2035. $NVS x.com/i/broadcasts/1…

Together with ZERO Prostate Cancer and partners, we are sounding the bell to break down barriers in #ProstateCancer. Today, we joined the opening ceremony at the NYSE 🏛 to introduce real change for men’s health. 🎉 Learn more about Blitz The Barriers: go.novartis.social/4efpzbh #NYSE